Department of Hospital Pharmacy, Hospital Universitario La Paz, Madrid, Spain
Department of Hospital Pharmacy, Hospital Universitario La Paz, Madrid, Spain.
Eur J Hosp Pharm. 2021 Nov;28(Suppl 2):e66-e71. doi: 10.1136/ejhpharm-2019-002114. Epub 2020 Jun 26.
Early reversal of anticoagulation improves outcomes in major bleeding and emergency surgery. To reverse vitamin K antagonists (VKA), vitamin K in addition to prothrombin complex concentrate (PCC) is recommended. Dosing recommendations for VKA reversal provided by the manufacturer are 25-50 IU/kg depending on the baseline international normalised ratio (INR). Nevertheless, we recommend an initial fixed dose of 1000 IU, and additional 500 IU doses evaluated on a case-by-case basis. As there is a paucity of clinical data demonstrating the efficacy and safety of this strategy, we designed this study to assess the effectiveness and safety of a four-factor (4F)-PCC for VKA reversal following a fixed-dose strategy.
This was a retrospective study of adult patients who received 4F-PCC for VKA reversal. The primary outcome was INR correction. INR correction was achieved if the first INR draw after 4F-PCC was ≤1.5. Safety outcome was any confirmed thromboembolic event within 3 months after 4F-PCC. Secondary outcomes included activated partial thromboplastin time (aPTT) correction, as well as haemostatic effectiveness for bleeding patients.
A total of 145 patients were included: 106 (73.1%) in the bleeding group and 39 (26.9%) in the emergency surgery group. The INR target was reached in 102 (70.3%) patients (p<0.0001). In one case, a thromboembolic complication was possibly related to 4F-PCC. The aPTT ratio target was reached in 113 (77.9%) patients (p<0.0001), and 79 of the 106 (74.5%) patients reversed for bleeding achieved haemostatic effectiveness.
After 4F-PCC, the majority of patients achieved the target INR, meaning 4F-PCC is a useful modality for rapid INR reduction. The safety profile may be considered acceptable. Fixed-dose 4F-PCC was able to restore haemostasis rapidly while minimising the risk of adverse events and optimising available resources.
在大出血和急诊手术中,早期抗凝逆转可改善结局。为了逆转维生素 K 拮抗剂 (VKA),除了维生素 K 外,还建议使用凝血酶原复合物浓缩物 (PCC)。制造商提供的 VKA 逆转剂量建议为 25-50IU/kg,具体取决于基线国际标准化比值 (INR)。然而,我们建议初始固定剂量为 1000IU,并根据具体情况评估额外的 500IU 剂量。由于缺乏临床数据证明这种策略的有效性和安全性,我们设计了这项研究,以评估固定剂量策略下 4 因子 (4F)-PCC 用于 VKA 逆转的效果和安全性。
这是一项回顾性研究,纳入了接受 4F-PCC 治疗 VKA 逆转的成年患者。主要结局是 INR 纠正。如果在接受 4F-PCC 后首次 INR 检测值≤1.5,则认为 INR 纠正。3 个月内发生任何确诊的血栓栓塞事件则视为安全性结局。次要结局包括激活部分凝血活酶时间 (aPTT) 纠正以及出血患者的止血效果。
共纳入 145 例患者:106 例 (73.1%) 在出血组,39 例 (26.9%) 在急诊手术组。102 例 (70.3%) 患者达到 INR 目标 (p<0.0001)。1 例血栓栓塞并发症可能与 4F-PCC 有关。113 例 (77.9%) 患者的 aPTT 比值达到目标 (p<0.0001),106 例因出血接受逆转治疗的患者中有 79 例达到止血效果。
接受 4F-PCC 后,大多数患者达到了目标 INR,这意味着 4F-PCC 是一种快速降低 INR 的有效方法。安全性概况可能被认为是可以接受的。固定剂量的 4F-PCC 能够迅速恢复止血,同时最大限度地降低不良事件风险并优化可用资源。